| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | Q-STATE BIOSCIENCES, INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44NS125689 | Ultra-high-throughput plate reader for drug discovery using all-optical electrophysiology | 000 | 4 | NIH | 2/12/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = -$871,896 ) |
| | 2024 | 2024 | Q-STATE BIOSCIENCES, INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44NS125689 | Ultra-high-throughput plate reader for drug discovery using all-optical electrophysiology | 000 | 7 | NIH | 8/13/2024 | $251,085 |
| | 2024 | 2022 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 000 | 2 | NIH | 11/23/2023 | $0 |
| | 2024 | 2022 | Q-STATE BIOSCIENCES, INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 001 | 2 | NIH | 1/8/2024 | -$404,281 |
| | 2024 | 2022 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH122052 | Functional drug fingerprinting with all-optical electrophysiology | 000 | 3 | NIH | 11/15/2023 | $0 |
| | 2024 | 2022 | Q-STATE BIOSCIENCES, INC | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44MH122052 | Functional drug fingerprinting with all-optical electrophysiology | 001 | 3 | NIH | 11/28/2023 | -$718,700 |
|
| Issue Date FY: 2023 ( Subtotal = -$122,530 ) |
| | 2023 | 2023 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44NS125689 | Ultra-high-throughput plate reader for drug discovery using all-optical electrophysiology | 002 | 6 | NIH | 9/15/2023 | $961,962 |
| | 2023 | 2022 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 002 | 2 | NIH | 7/12/2023 | $0 |
| | 2023 | 2022 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 001 | 2 | NIH | 1/17/2023 | -$49,429 |
| | 2023 | 2022 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44NS125689 | Ultra-high-throughput plate reader for drug discovery using all-optical electrophysiology | 000 | 4 | NIH | 9/8/2023 | -$1,024,439 |
| | 2023 | 2021 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R43NS117263 | An antisense oligonucleotide therapy for KCNT1 based epileptic encephalopathies | 000 | 2 | NIH | 8/11/2023 | $0 |
| | 2023 | 2021 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH112273 | Scalable, all-optical assays of synaptic function and plasticity | 000 | 5 | NIH | 12/1/2022 | $0 |
| | 2023 | 2019 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 000 | 1 | NIH | 1/17/2023 | -$10,624 |
|
| Issue Date FY: 2022 ( Subtotal = $4,681,270 ) |
| | 2022 | 2022 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 002 | 2 | NIH | 8/11/2022 | $60,053 |
| | 2022 | 2022 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 000 | 2 | NIH | 7/29/2022 | $995,203 |
| | 2022 | 2022 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44NS125689 | Ultra-high-throughput plate reader for drug discovery using all-optical electrophysiology | 000 | 4 | NIH | 9/13/2022 | $1,500,000 |
| | 2022 | 2022 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44MH122052 | Functional drug fingerprinting with all-optical electrophysiology | 000 | 3 | NIH | 7/19/2022 | $1,296,058 |
| | 2022 | 2020 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R43MH122052 | Functional drug fingerprinting with all-optical electrophysiology | 000 | 2 | NIH | 9/8/2022 | $0 |
| | 2022 | 2020 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R43NS115350 | Targeting ALS-linked FUS with allele-specific antisense oligonucleotides | 000 | 1 | NIH | 12/20/2021 | -$6,093 |
| | 2022 | 2020 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44NS107041 | An all-optical electrophysiology platform for the discovery of pain therapeutics | 000 | 3 | NIH | 3/21/2022 | $0 |
| | 2022 | 2020 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH112474 | Optopatch:high-throughput all-optical electrophysiology | 000 | 6 | NIH | 5/19/2022 | $0 |
| | 2022 | 2019 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 001 | 1 | NIH | 8/11/2022 | -$60,053 |
| | 2022 | 2019 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R43MH122924 | Anti-sense oligonucleotide platform for rare genetic diseases of the nervous system | 000 | 1 | NIH | 4/6/2022 | $0 |
| | 2022 | 2018 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R43MH113447 | Rapid, in vitro phenotyping of monogenic neurological disorders using CRISPRi and high-throughput all-optical electrophysiology. | 002 | 2 | NIH | 12/15/2021 | $0 |
| | 2022 | 2018 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R43MH114781 | All-optical electrophysiology in brain slice for drastically increased throughput | 000 | 2 | NIH | 4/6/2022 | $0 |
| | 2022 | 2018 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R43MH113447 | Rapid, in vitro phenotyping of monogenic neurological disorders using CRISPRi and high-throughput all-optical electrophysiology. | 001 | 2 | NIH | 10/20/2021 | $550,626 |
| | 2022 | 2017 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44HL126314 | High-throughput, all-optical assay in human cardiomyoctes for clinically relevant prediction of drug induced cardiotoxity. | 000 | 3 | NIH | 9/26/2022 | $5 |
| | 2022 | 2017 | Q-STATE BIOSCIENCES | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R43MH113447 | Rapid, in vitro phenotyping of monogenic neurological disorders using CRISPRi and high-throughput all-optical electrophysiology. | 000 | 1 | NIH | 10/20/2021 | $345,471 |
|
| Issue Date FY: 2021 ( Subtotal = $789,123 ) |
| | 2021 | 2021 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH112273 | Scalable, all-optical assays of synaptic function and plasticity | 001 | 5 | NIH | 2/24/2021 | $713,034 |
| | 2021 | 2021 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R43NS117263 | An antisense oligonucleotide therapy for KCNT1 based epileptic encephalopathies | 001 | 2 | NIH | 9/10/2021 | $76,089 |
| | 2021 | 2020 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH112273 | Scalable, all-optical assays of synaptic function and plasticity | 000 | 4 | NIH | 11/5/2020 | $0 |
| | 2021 | 2020 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R43NS117263 | An antisense oligonucleotide therapy for KCNT1 based epileptic encephalopathies | 000 | 1 | NIH | 9/6/2021 | $0 |
| | 2021 | 2020 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH112474 | Optopatch:high-throughput all-optical electrophysiology | 000 | 6 | NIH | 11/4/2020 | $0 |
| | 2021 | 2019 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 000 | 1 | NIH | 5/19/2021 | $0 |
| | 2021 | 2019 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4345 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 001 | 1 | NIH | 8/4/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,723,993 ) (Continued on the next page) |
| | 2020 | 2020 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R43MH122052 | Functional drug fingerprinting with all-optical electrophysiology | 000 | 2 | NIH | 9/2/2020 | $434,945 |
| | 2020 | 2020 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R43NS115350 | Targeting ALS-linked FUS with allele-specific antisense oligonucleotides | 000 | 1 | NIH | 1/21/2020 | $236,911 |
| | 2020 | 2020 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH112273 | Scalable, all-optical assays of synaptic function and plasticity | 000 | 4 | NIH | 2/19/2020 | $771,167 |
| | 2020 | 2020 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44NS107041 | An all-optical electrophysiology platform for the discovery of pain therapeutics | 001 | 3 | NIH | 8/28/2020 | $1,000,946 |
| | 2020 | 2020 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R43NS117263 | An antisense oligonucleotide therapy for KCNT1 based epileptic encephalopathies | 000 | 1 | NIH | 9/19/2020 | $451,550 |
| | 2020 | 2020 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH112474 | Optopatch:high-throughput all-optical electrophysiology | 000 | 6 | NIH | 4/22/2020 | $724,571 |
| | 2020 | 2019 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R43CA224563 | Developing an in vitro model for cancer pain using all-optical electrophysiology | 000 | 2 | NIH | 5/2/2020 | $0 |
| | 2020 | 2019 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R44MH121169 | A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | 000 | 1 | NIH | 7/24/2020 | $0 |
| | 2020 | 2018 | Q-STATE BIOSCIENCES, INC. | 179 SIDNEY ST | CAMBRIDGE | MA | 02139-4238 | MIDDLESEX | USA | R43MH114781 | All-optical electrophysiology in brain slice for drastically increased throughput | 000 | 2 | NIH | 7/16/2020 | $0 |
|
